

31

 참고 문헌

1. 김택윤. 골밀도 측정의 올바른 임상적용. 대한핵의학회지 2004;38:275-81.
2. 김소라, 채희동. 폐경 여성의 저용량 호르몬 요법. 대한폐경학회지 2010;16:65-70.
3. 김훈, 최영민. 혈관운동증상에 대한 비호르몬 치료. 대한경회지 2007;13:157-63.
4. 대한폐경학회. 폐경기 여성의 관리. 제3판. 서울: 군자출판사; 2007: 118-9.
5. 이병석, 황주연, 원형재, 박주현, 박기현, 조동제 등. 폐경여성에서 저용량 홀몬 요법시 혈중 지질단백질 및 골밀도의 변화. 대한폐경학회지 2004;10:249-54
6. 최훈, 이홍균, 박형무. 한국 폐경여성의 폐경에 대한 인식도 조사. 대한폐경회지 2003;9:36-43.
7. Abdali K, Khajehei M, Tabatabaee HR. Effect of St John's wort on severity, frequency, and duration of hot flashes in premenopausal, perimenopausal and postmenopausal women: a randomized, double-blind, placebo-controlled study. Menopause 2010;17:326-31.
8. Affinito P, Palomba S, Sammartino A, Bonifacio M, Nappi C. Ultrasonographic endometrial monitoring during continuous-sequential hormonal replacement therapy regimen in postmenopausal women. Maturitas 2001;39:239-44.
9. Aguirre W, Chedraui P, Mendoza J, Ruilova I. Gabapentin vs. low-dose transdermal estradiol for treating post-menopausal women with moderate to very severe hot flashes. Gynecol Endocrinol 2010;26:333-7.
10. Anderson GL, Judd HL, Kaunitz AM, Barad DH, Beresford SAA, Pettinger M, et al. Effects of estrogen plus progestin on gynecologic cancers and associated diagnostic procedures: The Women's Health Initiative randomized trial. JAMA 2003;290:1739-48.
11. Archer DF, Dorin M, Lewis V, Schneider DL, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on endometrial bleeding. Fertil Steril 2001;75:1080-7.
12. Archer DF, Henddrix S, Gallagher JC, Rymer J, Skouby S, Ferenczy A, et al. Endometrial effects of tibolone. J Clin Endocrinol Metab 2007;92:911-8
13. Archer DF, Pickar JH, Bottiglioni F. Bleeding patterns in postmenopausal women taking continuous combined or sequential regimens of conjugated estrogens with medroxyprogesterone acetate. Menopause Study Group. Obstet Gynecol 1994;83:686-92.
14. Archer DF, Seidman L, Constantine GD, Pickar JH, Olivier S. A double-blind, randomly assigned, placebo-controlled study of desvenlafaxine efficacy and safety for the treatment of vasomotor symptoms associated with menopause. Am J Obstet Gynecol 2009;200:172.e1-10.
15. Aston-Jones G, Shipley MT, Chouvet G, Ennis M, van Bockstaele E, Pieribone V, et al. Afferent regulation of locus coeruleus neurons: anatomy, physiology and pharmacology. Prog Brain Res 1991;88:47-75.
16. Atkinson C, Warren RM, Sala E, Dowsett M, Dunning AM, Healey CS, et al. Red-clover-derived isoflavones and mammographic breast density: a double-blind, randomized, placebo-controlled trial. Breast Cancer Res 2004;6:R170-9.
17. Avis NE, Crawford SL, McKinlay SM. Psychosocial, behavioral, and health factors related to menopause symptomatology. Womens Health 1997;3:103-20.
18. Azmitia EC, Gannon PJ. The primate serotonergic system: a review of human and animal studies and a report on Macaca fascicularis. Adv Neurol 1986;43:407-68.
19. Baber RJ, Templeman C, Morton T, Kelly GE, West L. Randomized placebo-controlled trial of an isoflavone supplement and menopausal symptoms in women. Climacteric 1999;2:85-

- 92.
20. Bachmann G, Lobo RA, Gut R, Nachtigall L, Notelovitz M. Efficacy of low-dose estradiol vaginal tablets in the treatment of atrophic vaginitis: a randomized controlled trial. *Obstet Gynecol* 2008;111:67-76.
21. Bachmann GA, Schaefer M, Uddin A, Utian WH. Micro-dose transdermal estrogen therapy for relief of vulvovaginal symptoms in postmenopausal women. *Menopause* 2009;16:877-82.
22. Bachmann GA, Timmons MC, Abernethy WD. Break-through bleeding patterns in two continuous combined estrogen/progestogen hormone replacement therapies, one of which included androgens. *J Womens Health Gend Based Med* 1996;5:205-12.
23. Bakos O, Smith P, Heimer G. Transvaginal ultrasonography for identifying endometrial pathology in postmenopausal women. *Maturitas* 1994;20:181-9.
24. Barakat RR, Bundy BN, Spirtos NM, Bell J, Mannel RS; Gynecologic Oncology Group Study. Randomized double-blind trial of estrogen replacement therapy versus placebo in stage I or II endometrial cancer: a Gynecologic Oncology Group Study. *J Clin Oncol* 2006;24:587-92.
25. Barrett-Conner E, Young RH, Notelovitz M, Sullivan J, Wiita B, Yang HM, et al. A two-year, double-blind comparison of estrogen-androgen and conjugated estrogens in surgically menopausal women. Effects on bone mineral density, symptoms and lipid profiles. *J Reprod Med* 1999;44:1012-20.
26. Barrett-Connor E, Timmons C, Young R, Witta B, and the Estratest Working Group. Interim safety analysis of a two-year study comparing oral estrogen-androgen and conjugated estrogens in surgically menopausal women. *J Womens Health* 1996;5:593-602.
27. Blumel JE, Castelo-Branco C, Rocagliolo ME, Bifa L, Tacla X, Mamani L. Changes in body mass index around menopause: a population study of Chilean woman. *Menopause* 2001;8:239-44.
28. Borrelli F, Ernst E. Alternative and complementary therapies for the menopause. *Maturitas* 2010;66:333-43.
29. Borrelli F, Ernst E. Black cohosh (*Cimicifuga racemosa*) for menopausal symptoms: a systematic review of its efficacy. *Pharmacol Res* 2008;58:8-14.
30. Borud EK, Alraek T, White A, Fonnebo V, Eggen AE, Hammar M, et al. The Acupuncture on Hot Flushes Among Menopausal Women (ACUFLASH) study, a randomized controlled trial. *Menopause* 2009;16:484-93.
31. Borud EK, Alraek T, White A, Grimsgaard S. The Acupuncture on Hot Flushes Among Menopausal Women study: observational follow-up results at 6 and 12 months. *Menopause* 2010;17:262-8.
32. Bots ML, Evans GW, Riley W, McBride KH, Paskett ED, Helmond FA, et al. The effect of tibolone and continuous combined conjugated equine oestrogens plus medroxyprogesterone acetate on progression of carotid intima-media thickness. *Eur Heart J* 2006;27:746-55.
33. Buckler HM, Robertson WR, Wu FCW. Which androgen replacement therapy for women? *J Clin Endocrinol Metab* 1998;83:3920-4.
34. Burger HG, Dudley EC, Cui J, Dennerstein L, Hopper J. A prospective longitudinal study of serum testosterone, dehydroepiandrosterone sulfate, and sex hormone-binding globulin levels through the menopause transition. *J Clin Endocrinol Metab* 2000;85:2832-8.
35. Butt DA, Lock M, Lewis JE, Ross S, Moineddin R. Gabapentin for the treatment of menopausal hot flashes: a randomized controlled trial. *Menopause* 2008;15:310-8.
36. Carbonell JL, Acosta R, Heredia B, Perez Y, Yero Castaneda MC, Hernandez AV. Mifepristone for the treatment of uterine leiomyomas. *Obstet Gynecol* 2008;112:1029-37.
37. Castelo-Branco C, Vicente J, Figueras F, Sanjuan A, Martinez de Osaba MJ, Casals E, et al. Comparative effects of estrogens plus androgens and tibolone on bone, lipid pattern and sexuality in postmenopausal women. *Maturitas* 2000;34:161-8.
38. Cauley JA, Black DM, Barrett-Connor E, Harris F, Shields K, Applegate W, et al. Effects of hormone replacement therapy on clinical fractures and height loss: The Heart and Estrogen/Progestin Replacement Study (HERS). *Am J Med* 2001;110:442-50.
39. Cauley JA, Robbins J, Chen Z, Cummings SR, Jackson RD, LaCroix AZ, et al. Effects of estrogen plus progestin on risk of fracture and bone mineral density: the Women's Health Initiative randomized trial. *JAMA* 2003;290:1729-38.
40. Chen Z, Bassford T, Green SB, Cauley JA, Jackson RD, LaCroix AZ, et al. Postmenopausal hormone therapy and body composition--a substudy of the estrogen plus progestin trial of the Women's Health Initiative. *Am J Clin Nutr* 2005;82:651-6.
41. Chlebowski RT, Anderson GL, Gass M, Lane DS, Aragaki AK, Kuller LH, et al. Estrogen plus progestin and breast cancer incidence and mortality in postmenopausal women. *JAMA* 2010;304:1684-92.
42. Chlebowski RT, Hendrix SL, Langer RD, Stefanick ML, Gass M, Lane D, et al. Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: The Women's Health Initiative randomized trial. *JAMA* 2003;289:3243-53.

43. Chlebowski RT, Wactawski-Wende J, Ritenbaugh C, Hubbell FA, Ascensao J, Rodabough R, et al. Estrogen plus progestin and colorectal cancer in postmenopausal women. *N Engl J Med* 2004;350:991-1004.
44. Chwalisz K, Elger W, Stickler T, Goldberg CM, Larsen L. The effects of 1-month administration of asoprisnil (J867), a selective progesterone receptor modulator, in healthy premenopausal women. *Hum Reprod* 2005;20:1090-99.
45. Chwalisz K, Larsen L, Goldberg CM, Edmonds A, Elger W, Winkel CA. A randomized, controlled trial of asoprisnil, a novel selective progesterone receptor modulator in women with uterine leiomyomata. *Fertil Steril* 2007;87:1399-412.
46. Collaborative group on hormonal factors in breast cancer. Breast cancer and hormone replacement therapy: collaborative reanalysis of data from 51 epidemiological studies of 52,705 women with breast cancer and 108,411 women without breast cancer. *Lancet* 1997;350:1047-59.
47. Colvin PL Jr, Auerbach BJ, Koritnik DR, Hazzard WR, Applebaum-Bowden D. Differential effects of oral estrone versus 17 beta-estradiol on lipoproteins in postmenopausal women. *J Clin Endocrinol Metab* 1990;70:1568-73.
48. Coughlin SS, Guiozzini AG, Smith SJ, Lee NC. A meta-analysis of estrogen replacement therapy and risk of epithelial ovarian cancer. *J Clin Epidemiol* 2000;53:367-75.
49. Crawford SL, Casey VA, Avis NE, McKinlay SM. A longitudinal study of weight and the menopause transition: results from the Massachusetts Women's Health Study. *Menopause* 2000;7:96-104.
50. Cummings JA, Brizendine L. Comparison of physical and emotional side effects of progesterone or medroxyprogesterone in early postmenopausal women. *Menopause* 2002;9:253-63.
51. Cummings SR, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verwij P, et al. The effects of tibolone in older postmenopausal women. *N Engl J Med* 2008;359:697-708.
52. Cummings SR, Palermo L, Browner W, Marcus R, Wallace R, Pearson J, et al. Monitoring osteoporosis therapy with bone densitometry: misleading changes and regression to the mean. *Fracture Intervention Trial Research Group. JAMA* 2000;283:1318-21.
53. Cummings SR, Ettinger BM, Ettinger B, Delmas PD, Kenemans P, Stathopoulos V, Verwij P, et al. The effects of tibolone in older postmenopausal women. *New Engl J Med* 2008;359:697-708.
54. Curb JD, Prentice RL, Bray PF, Langer RD, Horn LV, Barnabei VM, et al. Venous thrombosis and conjugated equine estrogen in women without a uterus. *Arch Intern Med* 2006;166:772-80.
55. Cushman M, Kuller LH, Prentice R, Rodabough RJ, Psaty BM, Stafford RS, et al. Estrogen plus progestin and risk of venous thrombosis. *JAMA* 2004;292:1573-80.
56. Daley AJ, Stokes-Lampard HJ, Macarthur C. Exercise to reduce vasomotor and other menopausal symptoms: a review. *Maturitas* 2009;63:176-80.
57. Daling JR, Malone KE, Doody DR, Voigt LF, Bernstein L, Coates RJ, et al. Relation of regimens of combined hormone replacement therapy to lobular, ductal, and other histologic types of breast carcinoma. *Cancer* 2002;95:2455-64.
58. Davies A, Hendrich J, Van Minh AT, Wratten J, Douglas L, Dolphin AC. Functional biology of the alpha(2)delta subunits of voltage-gated calcium channels. *Trends Pharmacol Sci* 2007;28:220-8.
59. Davis SR, Davison SL, Donath S, Bell RJ. Circulating androgen levels and self-reported sexual function in women. *JAMA* 2005;294:91-6.
60. Davis SR, Hirschberg AL, Wagner LK, Lodhi I, Von Schoultz B. The effect of transdermal testosterone on mammographic density in postmenopausal women not receiving systemic estrogen therapy. *J Clin Endocrinol Metab* 2009;94:4907-13.
61. Davis SR, McCloud P, Strauss BJG, Burger H. Testosterone enhances estradiol's effects on postmenopausal bone density and sexuality. *Maturitas* 1995;21:227-36.
62. Davis SR, Moreau M, Kroll R, Bouchard C, Panay N, Gass M, et al. Testosterone for low libido in postmenopausal women not taking estrogen. *New Engl J Med* 2008;359:2005-17.
63. Davis SR, van der Mooren MJ, van Lunsen RHW, Lopes P, Ribot C, Rees M, et al. Efficacy and safety of a testosterone patch for the treatment of hypoactive sexual desire disorder in surgically menopausal women: a randomized, placebo-controlled trial. *Menopause* 2006;13:387-96.
64. Davison S, Davis SR. New markers for cardiovascular disease risk in women: impact of endogenous estrogen status and exogenous postmenopausal hormone therapy. *J Clin Endocrinol Metab* 2003;88:2470-8.
65. Delmas PD, Pornel B, Felsenberg D, Stakkestad JA, Radawicki S, Garnero P, et al. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women. *Am J Obstet Gynecol* 2001;184:32-40.
66. Devogelaer JP, Lecart C, Dupret P, De Nayer P, Nagant De Deuxchaisnes C. Long-term effects of percutaneous estradiol on bone loss and bone metabolism in postmenopausal hysterectomized women. *Maturitas* 1998;28:243-9.
67. Dimitrakakis C, Zhou J, Wang J, Belanger A, Labrie F, Cheng C, et al. A physiologic role for testosterone in limiting estro-

- genic stimulation of the breast. *Menopause* 2003;10:292-8.
68. Doren M, Rubig A, Coelingh Benink HJT, Holzgreve W. Differential effects on the androgen status of postmenopausal women treated with tibolone and continuous combined estradiol and nore-thindrone acetate replacement therapy. *Fertil Steril* 2001;75:554-9
69. Elshafie MA, Ewies AA. Transdermal natural progesterone cream for postmenopausal women; inconsistent data and complex pharmacokinetics. *J Obstet Gynaecol* 2007;27:655-9.
70. EMAS Revised Statement. *Maturitas* 2005;51:8-14.
71. Espeland MA, Stefanick ML, Kritz-Silverstein D, Fineberg SE, Waclawiw MA, James MK, et al. Effect of postmenopausal hormone therapy on body weight and waist and hip girths. Postmenopausal Estrogen-Progestin Interventions Study Investigators. *J Clin Endocrinol Metab* 1997;82:1549-56.
72. Ettinger B, Ensrud KE, Wallace R, Johnson KC, Cummings SR, Yankov V, et al. Effects of ultralow-dose transdermal estradiol on bone mineral density: a randomized clinical trial. *Obstet Gynecol* 2004;104:443-51.
73. Ettinger B, Grady D, Tosteson AN, Pressman A, Macer JL. Effect of the Women's Health Initiative on women's decisions to discontinue postmenopausal hormone therapy. *Obstet Gynecol* 2003;102:1225-32.
74. Evans ML, Pritts E, Vittinghoff E, McClish K, Morgan KS, Jaffe RB. Management of postmenopausal hot flushes with venlafaxine hydrochloride: a randomized, controlled trial. *Obstet Gynecol* 2005;105:161-6.
75. Fedele L, Bianchi S, Raffaelli R, Zanconato G. A randomized study of the effects of tibolone and transdermal estrogen replacement therapy in postmenopausal women with uterine myomas. *Eur J Obstet Gynecol Reprod Biol* 2000;88:91-4
76. Feldman S, Shapter A, Welch WR, Berkowitz RS. Two-year follow-up of 263 patients with post/perimenopausal vaginal bleeding and negative initial biopsy. *Gynecol Oncol* 1994;55:56-9.
77. Field CS, Ory SJ, Wahner HW, Herrmann RR, Judd HL, Riggs BL. Preventive effects of transdermal 17 beta-estradiol on osteoporotic changes after surgical menopause: a two-year placebo-controlled trial. *Am J Obstet Gynecol* 1993;168:114-21.
78. Fosbery WHS. Severe climacteric flushings successfully treated by ovarian extract. *Br Med J* 1897; 1: 1039.
79. Fournier A, Berrino F, Clavel-Chapelon F. Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. *Breast Cancer Res Treat* 2008;107:103-11.
80. Freedman RR. Pathophysiology and treatment of menopausal hot flashes. *Semin Reprod Med* 2005;23:117-25.
81. Frei-Kleiner S, Schaffner W, Rahlfs VW, Bodmer Ch, Birkhauser M. *Cimicifuga racemosa* dried ethanolic extract in menopausal disorders: a double-blind placebo-controlled clinical trial. *Maturitas* 2005;51:397-404.
82. Fritz MA, Speroff L. *Clinical gynecologic endocrinology and infertility*. 8th ed. New York: Lippincott Williams & Wilkins 2010; p.763-5.
83. Gallagher JC, Baylink DJ, Freeman R, McClung M. Prevention of bone loss with tibolone in postmenopausal women: results of two randomized double-blind, placebo-controlled, dose-finding studies. *J Clin Endocrinol Metab* 2001;86:4717-26
84. Gallagher JC, Rapuri PB, Haynatzki G, Detter JR. Effect of discontinuation of estrogen, calcitriol, and the combination of both on bone density and bone markers. *J Clin Endocrinol Metab* 2002;87:4914-23.
85. Gambacciani M, Ciaponi M, Cappagli B, De Simone L, Orlandi R, Genazzani AR. Prospective evaluation of body weight and body fat distribution in early postmenopausal women with and without hormonal replacement therapy. *Maturitas* 2001;39:125-32.
86. Gambrell RD Jr. Use of progestogen therapy. *Am J Obstet Gynecol* 1987;156:1304-13.
87. Garnett T, Studd J, Watson N, Savvas M, Leather A. The effects of plasma estradiol levels on increases in vertebral and femoral bone density following therapy with estradiol and estradiol with testosterone implants. *Obstet Gynecol* 1992;79:968-72.
88. Geller SE, Shulman LP, van Breemen RB, Banuvar S, Zhou Y, Epstein G, et al. Safety and efficacy of black cohosh and red clover for the management of vasomotor symptoms: a randomized controlled trial. *Menopause* 2009;16:1156-66.
89. Ginsburg J, Prelevic GM. Cause of vaginal bleeding in postmenopausal women taking tibolone. *Maturitas* 1996;24:107-10
90. Goebelsmann U, Mashchak CA, Mishell DR Jr. Comparison of hepatic impact of oral and vaginal administration of ethinyl estradiol. *Am J Obstet Gynecol* 1985;151:868-77.
91. Goldstein SR, Zeltser I, Horan CK, Snyder JR, Schwartz LB. Ultrasonography-based triage for perimenopausal patients with abnormal uterine bleeding. *Am J Obstet Gynecol* 1997;177:102-8.
92. Gordon PR, Kerwin JP, Boesen KG, Senf J. Sertraline to treat hot flashes: a randomized controlled, double-blind, crossover trial in a general population. *Menopause* 2006;13:568-75.
93. Grady D, Cohen B, Tice J, Kristof M, Olyae A, Sawaya GF. Ineffectiveness of sertraline for treatment of menopausal hot

- flushes: a randomized controlled trial. *Obstet Gynecol* 2007;109:823-30.
94. Grady D, Gebretsadik T, Kerlikowske K, Ernster V, Petitti D. Hormone replacement therapy and endometrial cancer risk: a meta-analysis. *Obstet Gynecol* 1995;85:304-13.
95. Grady D, Sawaya GF. Discontinuation of postmenopausal hormone therapy. *Am J Med* 2005;118:163-5.
96. Granberg S, Ylostalo P, Wikland M, Karlsson B. Endometrial sonographic and histologic findings in women with and without hormonal replacement therapy suffering from postmenopausal bleeding. *Maturitas* 1997;27:35-40.
97. Greendale GA, Espeland M, Slone S, Marcus R, Barrett-Connor E; PEPI Safety Follow-Up Study (PSFS) Investigators. Bone mass response to discontinuation of long-term hormone replacement therapy: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) Safety Follow-up Study. *Arch Intern Med* 2002;162:665-72.
98. Greendale GA, Reboussin BA, Hogan P, Barnabei VM, Shumaker S, Johnson S, et al. Symptom relief and side effects of postmenopausal hormones: results from the Postmenopausal Estrogen/Progestin Interventions Trial. *Obstet Gynecol* 1998;92:982-8.
99. Greenspan SL, Emkey RD, Bone HG III, Weiss SR, Bell NH, Downs RW Jr, et al. Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis. *Ann Intern Med* 2002;137:875-83.
100. Gregoriou O, Konidaris S, Botsis D, Papadia C, Makrakis E, Creatsas G. Long term effects of tibolone on postmenopausal women with uterine myomas. *Maturitas* 2001;40:95-9.
101. Greiser CM, Greiser EM, Doeren M. Menopausal hormone therapy and risk of ovarian cancer: systematic review and meta-analysis. *Hum Reprod Update* 2007;13:453-63.
102. Grodstein F, Manson JE, Colditz GA, Willett WC, Speizer FE, Stampfer MJ. A prospective, observational study of postmenopausal hormone therapy and primary prevention of cardiovascular disease. *Ann Intern Med* 2000;133:933-41.
103. Grodstein F, Manson JE, Stampfer MJ, Rexrode K. Postmenopausal hormone therapy and stroke: role of time since menopause and age at initiation of hormone therapy. *Arch Intern Med* 2008;168:861-6.
104. Grodstein F, Newcomb PA, Stampfer MJ. Postmenopausal hormone therapy and the risk of colorectal cancer: a review and meta-analysis. *Am J Med* 1999;106:574-82.
105. Grodstein F, Stampfer MJ, Manson JE, Colditz GA, Willett WC, Rosner B, et al. Postmenopausal estrogen and progestin use and the risk of cardiovascular disease. *N Engl J Med* 1996;335:453-61.
106. Guidozi F, Daponte A. Estrogen replacement therapy for ovarian carcinoma survivors: a randomized controlled trial. *Cancer* 1999;86:1013-8.
107. Guttuso T Jr, Kurlan R, McDermott MP, Kiebertz K. Gabapentin's effects on hot flashes in postmenopausal women: a randomized controlled trial. *Obstet Gynecol* 2003;101:337-45.
108. Hameed A, Brothwood T, Bouloux P. Delivery of testosterone replacement therapy. *Curr Opin Investig Drugs* 2003;4:1213-9.
109. Hammar M, Christau S, Nathorst-Boos J, Rud T, Garre K. A double-blind, randomised trial comparing the effects of tibolone and continuous combined hormone replacement therapy in postmenopausal women with menopausal symptoms. *Br J Obstet Gynaecol* 1998;105:904-11.
110. Hanggi W, Bersinger N, Altermatt HJ, Birkhauser MH. Comparison of transvaginal ultrasonography and endometrial biopsy in endometrial surveillance in postmenopausal HRT users. *Maturitas* 1997;27:133-43.
111. Harding FE. The oral treatment of ovarian deficiency with conjugated estrogens - Equine. *West J Surg Obstet Gynecol* 1944;52:31.
112. Hebert-Croteau N. A meta-analysis of hormone replacement therapy and colon cancer in women. *Cancer Epidemiol Biomarkers Prev* 1998;7:653-9.
113. Henderson VW, Benke KS, Green RC, Cupples LA, Farrer LA. Postmenopausal hormone therapy and Alzheimer's disease risk: interaction with age. *J Neurol Neurosurg Psychiatry* 2005;76:103-5.
114. Hendrix SL, Wassertheil-Smoller S, Johnson KC, Howard BV, Koopersberg C, Rossouw JE, et al. Effects of conjugated equine estrogen on stroke in the Women's Health Initiative. *Circulation* 2006;113:2425-34.
115. Hermann AC, Nafziger AN, Victory J, Kulawy R, Rocci ML Jr, Bertino JS Jr. Over-the-counter progesterone cream produces significant drug exposure compared to a food and drug administration-approved oral progesterone product. *J Clin Pharmacol* 2005;4:614-9.
116. Hickok LR, Toomey C, Speroff L. A comparison of esterified estrogens with and without methyltestosterone: effects on endometrial histology and serum lipoproteins in postmenopausal women. *Obstet Gynecol* 1993;82:919-24.
117. Hildebrand JS, Gapstur SM, Feigelson HS, Teras LR, Thun MJ, Patel AV. Postmenopausal hormone use and incident ovarian cancer: associations differ by regimen. *Int J Cancer* 2010;127:2928-35.

118. Hilditch JR, Lewis J, Peter A, van Maris B, Ross A, Franssen E, et al. A menopause-specific quality of life questionnaire: development and psychometric properties. *Maturitas* 1996;24:161-75.
119. Hofing M, Hirschberg AL, Skoog L, Tani E, Hagerstrom T, von Schoultz B. Testosterone inhibits estrogen/progestin-induced breast cell proliferation in postmenopausal women. *Menopause* 2007;14:183-90.
120. Holmberg L, Anderson H. HABITS (hormonal replacement therapy after breast cancer-is it safe?), a randomized comparison: trial stopped. *Lancet* 2004;363:453-5.
121. Holmberg L, Iversen OE, Rudenstam CM, Hammar M, Kumpulainen E, Jaskiewicz J, et al. Increased risk of recurrence after hormone replacement therapy in breast cancer survivors. *J Natl Cancer Inst* 2008;100:475-82.
122. Horsman A, Jones M, Francis R, Nordin C. The effect of estrogen dose on postmenopausal bone loss. *N Engl J Med* 1983;309:1405-7.
123. Hsia J, Langer RD, Manson JE, Kuller L, Johnson KC, Hendrix SL, et al. Conjugated equine estrogens and coronary heart disease. The Women's Health Initiative. *Arch Intern Med* 2006;166:357-65.
124. Huang A, Yaffe K, Vittinghoff E, Kuppermann M, Addis I, Hanes V, et al. The effect of ultralow-dose transdermal estradiol on sexual function in postmenopausal women. *Am J Obstet Gynecol* 2008;198:265.e1-7.
125. Huang KE, Baber R. Updated clinical recommendations for the use of tibolone in Asian women *Climacteric* 2010;13:317-27
126. Huang MI, Nir Y, Chen B, Schnyer R, Manber R. A randomized controlled pilot study of acupuncture for postmenopausal hot flashes: effect on nocturnal hot flashes and sleep quality. *Fertil Steril* 2006;86:700-10.
127. Hulley S, Grady D, Bush T, Furberg C, Herrington D, Riggs B, et al. Randomized trial of estrogen plus progestin for secondary prevention of coronary heart disease in postmenopausal women. *JAMA* 1998;280:605-13.
128. Humphrey LL, Chan BKS, Sox HC. Postmenopausal hormone replacement therapy and the primary prevention of cardiovascular disease. *Ann Intern Med* 2002;137:273-84.
129. IMS Revised Position Paper. *Climacteric* 2004;7:333-7.
130. Jaakkola S, Lyytinen H, Pukkala E, Ylikorkala O. Endometrial cancer in postmenopausal women using estradiol-progestin therapy. *Obstet Gynecol* 2009;114:1197-204.
131. Jacobs A, Wegewitz U, Sommerfeld C, Grossklaus R, Lampen A. Efficacy of isoflavones in relieving vasomotor menopausal symptoms - A systematic review. *Mol Nutr Food Res* 2009;53:1084-97.
132. Jensen LB, Vestergaard P, Hermann AP, Gram J, Eiken P, Abrahamsen B, et al. Hormone replacement therapy dissociates fat mass and bone mass, and tends to reduce weight gain in early postmenopausal women: a randomized controlled 5-year clinical trial of the Danish Osteoporosis Prevention Study. *J Bone Miner Res* 2003;18:333-42.
133. Jiroutek MR, Chen M-H, Johnston CC, Longcope C. Changes in reproductive hormones and sex hormone-binding globulin in a group of postmenopausal women measured over 10 years. *Menopause* 1998;5:90-4.
134. Johannessen Landmark C. Antiepileptic drugs in non-epilepsy disorders: relations between mechanisms of action and clinical efficacy. *CNS Drugs* 2008;22:27-47.
135. Johnson JR, Lacy JV Jr, Lazovich DA, Geller MA, Schairer C, Schatzkin A, et al. Menopausal hormone therapy and risk of colorectal cancer. *Cancer Epidemiol Biomarkers Prev* 2009;18:196-203.
136. Jung-Hoffman C, Kuhl H. Pharmacokinetics and pharmacodynamics of oral contraceptive steroids: factors influencing steroid metabolism. *Am J Obstet Gynecol* 1990;163:2183-97.
137. Karlsson B, Granberg S, Wikland M, Ylostalo P, Torvid K, Marsal K, et al. Transvaginal ultrasonography of the endometrium in women with postmenopausal bleeding--a Nordic multicenter study. *Am J Obstet Gynecol* 1995;172:1488-94.
138. Kenemans P, Bundred N, Foidart JM, Kubista E, von Schoultz B, Sisoni P, et al. Safety and efficacy of tibolone in breastcancer patients with vasomotor symptoms: a double-blind, randomized, non-inferiority trial. *Lancet Oncol* 2009;10:135-46.
139. Kenemans P, Bundred NJ, Foidart J-M, Kubista E, Von Schoultz B, Sisoni P, et al. Safety and efficacy of tibolone in breast-cancer patients with vasomotor symptoms: a double-blind, randomised, non-inferiority trial. *Lancet Oncol* 2009;10:135-46
140. Kenemans P, Speroff L. Tibolone: Clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group. *Maturitas* 2005;51:21-8.
141. Kirkham C, Hahn PM, Van Vugt DA, Carmichael JA, Reid RL. A randomized, double-blind, placebo-controlled, cross-over trial to assess the side effects of medroxyprogesteroneacetate in hormone replacement therapy. *Obstet Gynecol* 1991;78:93-7.
142. Kloosterboer HJ. Tibolone: a steroid with a tissue-specific mode of action. *J Steroid Biochem Md Biol* 2001;76:231-8
143. Knight DC, Howes JB, Eden JA. The effect of Promensil, an

- isoflavone extract, on menopausal symptoms. *Climacteric* 1999;2:79-84.
144. Komesaroff PA, Black CVS, Cable V, Sudhir K. Effects of wild yam extract on menopausal symptoms, lipids and sex hormones in healthy menopausal women. *Climacteric* 2001;4:144-50.
145. Konidala S, Gutterman DD. Coronary vasospasm and the regulation of coronary blood flow. *Prog Cardiovasc Dis* 2004;46:349-73.
146. Kritz-Silverstein D, Barrett-Connor E. Long-term postmenopausal hormone use, obesity, and fat distribution in older women. *JAMA* 1996;275:46-9.
147. Labrie F, Belanger A, Cusan L, Gomez J-L, Candas B. Marked decline in serum concentrations of adrenal C19 sex steroid precursors and conjugated androgen metabolites during aging. *J Clin Endocrinol Metab* 1997;82:2396-402.
148. LaCroix AZ, Chlebowski RT, Manson JE, Aragaki AK, Johnson KC, Martin L, et al. Health outcomes after stopping conjugated equine estrogens among postmenopausal women with prior hysterectomy: a randomized controlled trial. *JAMA* 2011;305:1305-14.
149. Langer RD, Pierce JJ, O'Hanlan KA, Johnson SR, Espeland MA, Trabala JF, et al. Transvaginal ultrasonography compared with endometrial biopsy for the detection of endometrial disease. *Postmenopausal Estrogen/Progestin Interventions Trial*. *N Engl J Med* 1997;337:1792-8.
150. LeBlanc ES, Janowsky J, Chan BKS, Nelson HD. Hormone replacement therapy and cognition: systematic review and metaanalysis. *JAMA* 2001;285:1489-99.
151. Lee DY, Na DL, Seo SW, Chin JH, Lim SJ, Choi DS, et al. Association between cognitive impairment and bone mineral density in postmenopausal women. *Menopause* 2012.
152. Leonetti, HB, Longo S, Anasti JN. Transdermal progesterone cream for vasomotor symptoms and postmenopausal bone loss. *Obstet Gynecol* 1999;94:225-8.
153. Levine D, Gosink BB, Johnson LA. Change in endometrial thickness in postmenopausal women undergoing hormone replacement therapy. *Radiology* 1995;197:603-8.
154. Lindsay R, Gallagher JC, Kleerekoper M, Pickar JH. Effect of lower doses of conjugated equine estrogens with and without medroxyprogesterone acetate on bone in early postmenopausal women. *JAMA* 2002;287:2668-76.
155. Lindsay R, Hart DM, Maclean A, Garwood J, Clark AC, Kraszewski A. Bone loss during oestriol therapy in postmenopausal women. *Maturitas* 1979;1:279-85.
156. Lobo RA, Bush T, Carr BR, Pickar JH. Effects of lower doses of conjugated equine estrogens and medroxyprogesterone acetate on plasma lipids and lipoproteins, coagulation factors, and carbohydrate metabolism. *Fertil Steril* 2001;76:13-24.
157. Longcope C, Franz C, Morello C, Baker RS, Johnston Jr CC. Steroid and gonadotropin levels in women during the perimenopausal years. *Maturitas* 1986;8:189-96.
158. Loprinzi CL, Sloan J, Stearns V, Slack R, Iyengar M, Diekmann B, et al. Newer antidepressants and gabapentin for hot flashes: an individual patient pooled analysis. *J Clin Oncol* 2009;27:2831-7.
159. Lundstrom E, Christow A, Kersemaekers W, Svane G, Azaavedo E, Soderqvist G, et al. Effects of tibolone and continuous combined hormone replacement therapy on mammographic breast density. *Am J Obstet Gynecol* 2002;186:717-22.
160. MacLennan A, Lester A, Moore V. Oral oestrogen replacement therapy versus placebo for hot flushes [Cochrane Review on CD-ROM]. Oxford, England: Cochrane Library, Update Software; 2002.
161. Madauss KP, Grygielko ET, Deng SJ, Sulpizio AC, Stanley TB, Wu C, et al. A Structural and in Vitro Characterization of Asoprisnil: A Selective Progesterone Receptor Modulator. *Mol Cell Endocrinol*. 2007;21:1066-81.
162. Magnusson C, Baron JA, Correia N, Bergström R, Adami HO, Persson I. Breast-cancer risk following long-term oestrogen and oestrogen-progestin replacement therapy. *Int J Cancer* 1999;81:339-44.
163. Manson JE, Allison MA, Rossouw JE, Carr JJ, Langer RD, Hsia J, et al. Estrogen therapy and coronary-artery calcification. *N Engl J Med* 2007;356:2591-602.
164. Manson JE, Hsia J, Johnson KC, Rossouw JE, Assaf AR, Lasser NL, et al. Estrogen and progestin and the risk of coronary heart disease. *N Engl J Med* 2003;349:523-34.
165. Meeuwse IB, Samson MM, Duursma SA, Verhaar HJ. The effect of tibolone on fat mass, fat-free mass, and total body water in postmenopausal women. *Endocrinology* 2001;142:4813-7.
166. Mendelsohn ME, Karas RH. Molecular and cellular basis of cardiovascular gender differences. *Science* 2005;308:1583-7.
167. Miller J, Chan BKS, Nelson HD. Postmenopausal estrogen replacement and risk for venous thromboembolism: a systematic review and meta-analysis for the U.S. Preventive Services Task Force. *Ann Intern Med* 2002;136:680-90.
168. Million Women Study Collaborators. Breast cancer and hormone replacement therapy in the Million Women Study. *Lancet* 2003;362:419-27.
169. Mulnard RA, Cotman CW, Kawas C, van Dyck CH, Sano M, Doody R, et al. Estrogen replacement therapy for treat-

- ment of mild to moderate Alzheimer Disease: a randomized controlled trial. *JAMA* 2000;283:1007-15.
170. Myers LS, Dixen J, Morrisette D, Carmichael M, Davidson JM. Effects of estrogen, androgen, and progestin on sexual psychophysiology and behavior in postmenopausal women. *J Clin Endocrinol Metab* 1990;70:1124-31.
171. Nand SL, Webster MA, Baber R, O'Connor V. Bleeding pattern and endometrial changes during continuous combined hormone replacement therapy. The Ogen/Provera Study Group. *Obstet Gynecol* 1998;91:678-84.
172. Nanda K, Bastian LA, Hasselblad V, Simel DL. Hormone replacement therapy and the risk of colorectal cancer: a metaanalysis. *Obstet Gynecol* 1999;93:880-8.
173. Nelson HD, Humphrey LI, Nygren P, Teutsch SM, Allan JD. Postmenopausal hormone replacement therapy: scientific review. *JAMA* 2002;288:872-81.
174. Nelson HD, Rizzo J, Harris E, Cauley J, Ensrud K, Bauer DC, et al. Osteoporosis and fractures in postmenopausal women using estrogen. *Arch Intern Med* 2002;162:2278-84.
175. Nelson HD, Vesco KK, Haney E, Fu R, Nedrow A, Miller J, et al. Nonhormonal therapies for menopausal hot flashes: systematic review and meta-analysis. *JAMA* 2006;295:2057-71.
176. Newton KM, Reed SD, Grothaus L, Ehrlich K, Guiltinan J, Ludman E, et al. The Herbal Alternatives for Menopause (HALT) Study: background and study design. *Maturitas* 2005;52:134-6.
177. Newton KM, Reed SD, LaCroix AZ, Grothaus LC, Ehrlich K, Guiltinan J. Treatment of vasomotor symptoms of menopause with black cohosh, multibotanicals, soy, hormone therapy, or placebo: a randomized trial. *Ann Intern Med* 2006;145:869-79.
178. Nijland EA, Weijmar Schultz WC, Nathorst-Boos J, Helmond FA, Van Lunsen RHW, Palacios S, et al. Tibolone and transdermal E2/NETA for the treatment of sexual dysfunction in naturally menopausal women: results of a randomized activecontrolled trial. *J Sex Med* 2008;5:646-56.
179. North American Menopause Society. Estrogen and progestogen use in postmenopausal women: 2010 position statement of The North American Menopause Society. *Menopause* 2010;17:242-55.
180. Notelovitz M. Estrogen therapy in the management of problems associated with urogenital ageing: a simple diagnostic test and the effect of the route of hormone administration. *Maturitas* 1995;22:S31-3.
181. O'Meara ES, Rossing MA, Daling JR, Elmore JG, Barlow WE, Weiss NS. Hormone replacement therapy after a diagnosis of breast cancer in relation to recurrence and mortality. *J Natl Cancer Inst* 2001;93:754-62.
182. Ockene JK, Barad DH, Cochrane BB, Larson JC, Gass M, Wassertheil-Smoller S et al. Symptom experience after discontinuing use of estrogen plus progestin. *JAMA* 2005;294:183-93.
183. Oktem M, Eroglu D, Karahan HB, Taskintuna N, Kuscü E, Zeyneloglu HB. Black cohosh and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized trial. *Adv Ther* 2007;24:448-61.
184. Osmer R, Friede M, Liske E, Schnitker J, Freudenstein J, Henneicke-von Zepelin HH. Efficacy and safety of isopropanolic black cohosh extract for climacteric symptoms. *Obstet Gynecol* 2005;105:1074-83.
185. Pandya KJ, Raubertas RF, Flynn PJ, Hynes HE, Rosenbluth RJ, Kirshner JJ, et al. Oral clonidine in postmenopausal patients with breast cancer experiencing tamoxifen-induced hot flashes: a University of Rochester Cancer Center Community Clinical Oncology Program study. *Ann Intern Med* 2000;132:788-93.
186. Pang SC, Greendale GA, Cedars MI, Gambone JC, Lozano K, Eggena P, et al. Long-term effects of transdermal estradiol with and without medroxyprogesterone acetate. *Fertil Steril* 1993;59:76-82.
187. Pickar JH, Yeh IT, Wheeler JE, Cunnane MF, Speroff L. Endometrial effects of lower doses of conjugated equine estrogen and medroxyprogesterone acetate: two-year substudy results. *Fertil Steril* 2003;80:1234-40.
188. Pike MC, Peters RK, Cozen W, Probst-Hensch NM, Felix JC, Wan PC, et al. Estrogen-progestin replacement therapy and endometrial cancer. *J Natl Cancer Inst* 1997;89:1110-6.
189. Prestwood KM, Kenny AM, Kleppinger A, Kulldorff M. Ultralow-dose micronized 17beta-estradiol and bone density and bone metabolism in older women: a randomized controlled trial. *JAMA* 2003;290:1042-8.
190. Prior JC, Alojado N, McKay DW, Vigna YM. No adverse effects of medroxyprogesterone treatment without estrogen in postmenopausal women: double-blind, placebo-controlled, crossover trial. *Obstet Gynecol* 1994;83:24-8.
191. Quinn SD, Domoney C. The effects of hormones on urinary incontinence in postmenopausal women. *Climacteric* 2009;12:106-13.
192. Rannevik G, Jeppsson S, Johnell O, Bjerre B, Yaurell-Borulf Y, Svanberg L. A longitudinal study of the perimenopausal transition: altered profiles of steroid and pituitary hormones, SHBG and bone mineral density. *Maturitas* 1995;21:103-13.
193. Raudaskoski T, Tapanainen J, Tomas E, Luotola H, Pekonen

- F, Ronni-Sivula H, et al. Intrauterine 10 microg and 20 microg levonorgestrel systems in postmenopausal women receiving oral oestrogen replacement therapy: clinical, endometrial and metabolic response. *BJOG* 2002;109:136-44.
194. Recker RR, Davies KM, Dowd RM, Heaney RP. The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women - a randomized, controlled trial. *Ann Intern Med* 1999;130:897-904.
195. Reddy SY, Warner H, Guttuso T Jr, Messing S, DiGrazio W, Thornburg L, et al. Gabapentin, estrogen, and placebo for treating hot flashes: a randomized controlled trial. *Obstet Gynecol* 2006;108:41-8.
196. Renoux C, Dell'Aniello S, Garbe E, Suissa S. Transdermal and oral hormone replacement therapy and the risk of stroke: a nested case-control study. *BMJ* 2010;340:c2519-25.
197. Renoux C, Dell'aniello S, Suissa S. Hormone replacement therapy and the risk of venous thromboembolism: populationbased study. *J Thromb Haemost* 2010;8:979-86.
198. Rewinkel J, Enthoven M, Golstein I, van der Rijst M, Scholten A, van Tilborg M, et al. 11-(Pyridinylphenyl)steroids-A new class of mixed-profile progesterone agonists/antagonists. *Bioorg Med Chem* 2008;16:2753-63.
199. Rice MM, Graves AB, McCurry SM, Gibbons LE, Bowen JD, McCormick WC, et al. Postmenopausal estrogen and estrogen-progestin use and 2-year rate of cognitive change in a cohort of older Japanese American women: the Kame project. *Arch Intern Med* 2000;160:1641-9.
200. Ritenbaugh C, Stanford JL, Wu LL, Shikany JM, Schoen RE, Stefanick ML, et al. Conjugated equine estrogens and colorectal cancer incidence and survival: The Women's Health Initiative randomized clinical trial. *Cancer Epidemiol Biomarkers Prev* 2008;17:2609-18.
201. Rocca WA, Bower JH, Maraganore DM, Ahlskog JE, Grossardt BR, de Andrade M, et al. Increased risk of cognitive impairment or dementia in women who underwent oophorectomy before menopause. *Neurology* 2007;69:1074-83.
202. Ross D, Rees M, Godfree V, Cooper A, Hart D, Kingsland C, et al. Randomised crossover comparison of skin irritation with two transdermal oestradiol patches. *BMJ* 1997;315:288.
203. Ross RK, Paganini-Hill A, Wan PC, Pike MC. Effect of hormone replacement therapy on breast cancer risk: estrogen versus estrogen plus progestin. *J Natl Cancer Inst* 2000;92:328-32.
204. Rossouw JE, Prentice RL, Manson JE, Wu L, Barad D, Barnabei VM, et al. Postmenopausal hormone therapy and risk of cardiovascular disease by age and years since menopause. *JAMA* 2007;297:1465-77.
205. Roy S, Caillouette JC, Roy T, Faden JS. Vaginal pH is similar to follicle-stimulating hormone for menopause diagnosis. *Am J Obstet Gynecol* 2004;190:1272-7.
206. Rymer J, Robinson J, Fogelman I. Ten years of treatment with tibolone 2.5mg daily: effects on bone loss in postmenopausal women. *Climacteric* 2002;5:390-8.
207. Schairer C, Lubin J, Troisi R, Sturgeon S, Brinton L, Hoover R. Menopausal estrogen and estrogen-progestin replacement therapy and breast cancer risk. *JAMA* 2000;283:485-91.
208. Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. *Maturitas* 1994;20:155-63.
209. Shams T, Setia MS, Hemmings R, McCusker J, Sewitch M, Ciampi A. Efficacy of black cohosh-containing preparations on menopausal symptoms: a meta-analysis. *Altern Ther Health Med* 2010;16:36-44.
210. Sherwin BB, Gelfand MM. The role of androgen in the maintenance of sexual functioning in oophorectomized women. *Psychosom Med* 1987;49:397-409.
211. Shifren JL, Braunstein GD, Simon JA, Casson PR, Buster JE, Redmond GP, et al. Transdermal testosterone treatment in women with impaired sexual function after oophorectomy. *New Eng J Med* 2000;343:682-8.
212. Shifren JL, Davis SR, Moreau M, Waldbaum A, Bouchard C, DeRogatis L, et al. Testosterone patch for the treatment of hypoactive sexual desire disorder in naturally menopausal women: results from the INTIMATE NM1 Study. *Menopause* 2006;13:770-9.
213. Shumaker SA, Legault C, Kuller L, Rapp SR, Thal L, Lane DS, et al. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women: Women's Health Initiative Memory Study. *JAMA* 2004;291:2947-58.
214. Shumaker SA, Legault C, Rapp SR, Thal L, Wallace RB, Ocikene JK, et al. Estrogen plus progestin and the incidence of dementia and mild cognitive impairment in postmenopausal women. the Women's Health Initiative Memory Study: a randomized controlled trial. *JAMA* 2003;289:2651-62.
215. Simon JA, Hsia J, Cauley JA, Richards C, Harris F, Fong J, et al. Postmenopausal hormone therapy and risk of stroke: the Heart and Estrogen-progestin Replacement Study (HERS). *Circulation* 2001;103:638-42.
216. Simon JA, Liu JH, Speroff L, Shumel BS, Symons JP. Reduced vaginal bleeding in postmenopausal women who receive combined norethindrone acetate and low-dose ethinyl

- estradiol therapy versus combined conjugated equine estrogens and medroxyprogesterone acetate therapy. *Am J Obstet Gynecol* 2003;188:92-9.
217. Simon JA, Symons JP. Unscheduled bleeding during initiation of continuous combined hormone replacement therapy: a direct comparison of two combinations of norethindrone acetate and ethinyl estradiol to medroxyprogesterone acetate and conjugated equine estrogens. *Menopause* 2001;8:321-7.
218. Sladkevicius P, Valentin L, Marsal K. Endometrial thickness and Doppler velocimetry of the uterine arteries as discriminators of endometrial status in women with postmenopausal bleeding: a comparative study. *Am J Obstet Gynecol* 1994;171:722-8.
219. Smith DC, Prentice R, Thompson DJ, Herrmann WL. Association of exogenous estrogen and endometrial carcinoma. *N Engl J Med* 1975;293:1164-7.
220. Soares CN, Joffe H, Viguera AC, Petrillo L, Rydzewski M, Yehezkel R, et al. Paroxetine versus placebo for women in midlife after hormone therapy discontinuation. *Am J Med* 2008;121:159-62.
221. Speroff L, Fritz MA. *Clinical gynecologic endocrinology and infertility*. 8th ed. Philadelphia: Wolters Kluwer 2011.
222. Speroff L, Gass M, Constantine G, Olivier S. Efficacy and tolerability of desvenlafaxine succinate treatment for menopausal vasomotor symptoms: a randomized controlled trial. *Obstet Gynecol* 2008;111:77-87.
223. Speroff L, Rowan J, Symons J, Genant H, Wilborn W. The comparative effect on bone density, endometrium, and lipids of continuous hormones as replacement therapy (CHART study). A randomized controlled trial. *JAMA* 1996;276:1397-403.
224. Stearns V, Beebe KL, Iyengar M, Dube E. Paroxetine controlled release in the treatment of menopausal hot flashes: a randomized controlled trial. *JAMA* 2003;289:2827-34.
225. Stearns V, Slack R, Greep N, Henry-Tilman R, Osborne M, Bunnell C, et al. Paroxetine is an effective treatment for hot flashes: results from a prospective randomized clinical trial. *J Clin Oncol* 2005;23:6919-30.
226. Stefanick ML, Anderson GL, Margolis KL, Hendrix SL, Rodabough RJ, et al. Effects of conjugated equine estrogens on breast cancer and mammography screening in postmenopausal women with hysterectomy. *JAMA* 2006;295:1647-57.
227. Sterns EE, Zee B. Mammographic density changes in perimenopausal and postmenopausal women: is effect of hormone replacement therapy predictable?. *Breast Cancer Res Treat* 2000;59:125-32.
228. Stevenson JC, Cust MP, Gangar KF, Hillard TC, Lees B, Whitehead MI. Effects of transdermal versus oral hormone replacement therapy on bone density in spine and proximal femur in postmenopausal women. *Lancet* 1990;335:265-9.
229. Straczek C, Oger E, Yon de Jonage-Canonico MB, Plu-Bureau G, Conard J, Meyer G, et al. Prothrombotic mutations, hormone therapy, and venous thromboembolism among postmenopausal women: impact of the route of estrogen administration. *Circulation* 2005;112:3495-500.
230. Sturdee DW, Pines A. Updated IMS recommendations on postmenopausal hormone therapy and Preventive strategies for midlife health. *Climacteric* 2011;14:302-20.
231. Sturdee DW, Ulrich LG, Barlow DH, Wells M, Campbell MJ, Vessey MP, et al. The endometrial response to sequential and continuous combined oestrogen-progestogen replacement therapy. *BJOG* 2000;107:1392-400.
232. Suriano KA, McHale M, McLaren CE, Li KT, Re A, DiSaia PJ. Estrogen replacement therapy in endometrial cancer patients: a matched control study. *Obstet Gynecol* 2001;97:555-60.
233. Suvanto-Luukkonen E, Koivunen R, Sundstrom H, Bloigu R, Karjalainen E, Haiva-Mallinen L, et al. Citalopram and fluoxetine in the treatment of postmenopausal symptoms: a prospective, randomized, 9-month, placebo-controlled, double-blind study. *Menopause* 2005;12:18-26.
234. Symons J, Kempfert N, Speroff L. Vaginal bleeding in postmenopausal women taking low-dose norethindrone acetate and ethinyl estradiol combinations. The FemHRT Study Investigators. *Obstet Gynecol* 2000;96:366-72.
235. Tamimi RM, Hankinson SE, Chen WY, Rosner B, Colditz GA. Combined estrogen and testosterone use and risk of breast cancer in postmenopausal women. *Arch Intern Med* 2006;166:1483-9.
236. Tan D, Haines CJ, Limpaphayom KK, Holinka CF, Ausmanas MK. Relief of vasomotor symptoms and vaginal atrophy with three doses of conjugated estrogens and medroxyprogesterone acetate in postmenopausal Asian women from 11 countries: The Pan-Asia menopause (PAM) study. *Maturitas* 2005;52:35-51.
237. Taskin O, Yalcinoglu AI, Kucuk S, Uryan I, Buhur A, Burak F. Effectiveness of tibolone on hypoestrogenic symptoms induced by goserelin treatment in patients with endometriosis. *Fertil Steril* 1997;67:40-5.
238. Taylor M. Bioidentical estrogens: Hope or hype? *Sexuality, Reproduction and menopause* 2005;3:68-71.
239. Taylor M. Alternative medicine and the perimenopause: an evidence-based review. *Obstet Gynecol Clin North Am* 2002;29:555-73.

240. The Writing Group for the PEPI Trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA* 1995;273:199-208.
241. The Writing Group for the PEPI Trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA* 1996;275:370-5.
242. The Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen/progestin interventions (PEPI) trial. The Writing Group for the PEPI. *JAMA* 1996;276:1389-96.
243. Thurston RC, Joffe H, Soares CN, Harlow BL. Physical activity and risk of vasomotor symptoms in women with and without a history of depression: results from the Harvard Study of Moods and Cycles. *Menopause* 2006;13:553-60.
244. Toulis KA, Tzellos T, Kouvelas D, Goulis DG. Gabapentin for the treatment of hot flashes in women with natural or tamoxifen-induced menopause: a systematic review and meta-analysis. *Clin Ther* 2009;31:221-35.
245. Urman B, Pride SM, Ho Yuen B. Elevated serum testosterone, hirsutism, and virilism associated with combined androgen/estrogen hormone replacement therapy. *Obstet Gynecol* 1991;77:595-8.
246. Utian WH, Shoupe D, Bachmann G, Pinkerton JV, Pickar JH. Relief of vasomotor symptoms and vaginal atrophy with lower doses of conjugated equine estrogens and medroxyprogesterone acetate. *Fertil Steril* 2001;75:1065-79.
247. Valdivia I, Ortega D. Mammographic density in postmenopausal women treated with tibolone, estriol or conventional hormone replacement therapy. *Clin Drug Invest* 2000;20:101-7.
248. van de Weijer PH, Barentsen R. Isoflavones from red clover (Promensil) significantly reduce menopausal hot flush symptoms compared with placebo. *Maturitas* 2002;42:187-93.
249. Van den Bosch T, Van Schoubroeck D, Ameye L, De Brabanter J, Van Huffel S, Timmerman D. Ultrasound assessment of endometrial thickness and endometrial polyps in women on hormonal replacement therapy. *Am J Obstet Gynecol* 2003;188:1249-53.
250. Varila E, Wahlstrom T, Rauramo I. A 5-year follow-up study on the use of a levonorgestrel intrauterine system in women receiving hormone replacement therapy. *Fertil Steril* 2001;76:969-73.
251. Varma TR. Effect of long-term therapy with estrogen and progesterone on the endometrium of post-menopausal women. *Acta Obstet Gynecol Scand* 1985;64:41-6.
252. Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. A study to look at hormonal absorption of progesterone cream used in conjunction with transdermal estrogen. *Gynecol Endocrinol* 2005;21:101-5.
253. Vashisht A, Wadsworth F, Carey A, Carey B, Studd J. Bleeding profiles and effects on the endometrium for women using a novel combination of transdermal oestradiol and natural progesterone cream as part of a continuous combined hormonal replacement regime. *BJOG* 2005;112:1402-6.
254. Vassilopoulou-Sellin R, Cohen DS, Hortobagyi GN, Klein MJ, McNeese M, Singletary SE, et al. Estrogen replacement therapy for menopausal women with a history of breast carcinoma: results of a 5-year, prospective study. *Cancer* 2002;95:1817-26.
255. Vereide AB, Arnes M, Straume B, Maltau JM, Ørbo A. Nuclear morphometric changes and therapy monitoring in patients with endometrial hyperplasia: a study comparing effects of intrauterine levonorgestrel and systemic medroxyprogesterone. *Gynecol Oncol* 2003;91:526-33.
256. Viscoli CM, Brass LM, Kernan WN, Sarrel PM, Suissa S, Horwitz RI. A clinical trial of estrogen-replacement therapy after ischemic stroke. *N Engl J Med* 2001;345:1243-9.
257. von Schoultz E, Rutqvist LE; Stockholm Breast Cancer Study Group. Menopausal hormone therapy after breast cancer: the Stockholm randomized trial. *J Natl Cancer Inst* 2005;97:533-5.
258. Walsh BW, Li H, Sacks FM. Effects of postmenopausal hormone replacement with oral and transdermal estrogen on high density lipoprotein metabolism. *J Lipid Res* 1994;35:2083-93.
259. Wassertheil-Smoller S, Hendrix SL, Limacher M, Heiss G, Kooperberg C, Baird A, et al. Effect of estrogen and progestin on stroke in postmenopausal women. The Women's Health Initiative: a randomized trial. *JAMA* 2003;289:2673-84.
260. Watts NB, Notelovitz M, Timmons MC, Addison WA, Wilita B, Downey LJ. Comparison of oral estrogens and estrogens plus androgens on bone mineral density, menopausal symptoms, and lipid-lipo-protein profiles in surgical menopause. *Obstet Gynecol* 1995;85:529-37.
261. Weber A, Jager R, Borner A, Klinger G, Vollandt R, Matthey K, et al. Can grapefruit juice influence ethinylestradiol bioavailability? *Contraception* 1996;53:41-7.
262. Weiss LK, Burkman RT, Cushing-Haugen KL, Voigt LF, Simon MS, Daling JR, et al. Hormone replacement therapy

- regimens and breast cancer risk. *Obstet Gynecol* 2002;100:1148-58.
263. Weiss NS. Editorial: Risks and benefits of estrogen use. *N Engl J Med* 1975;293:1200-2.
264. Weiss SR, Ellman H, Dolker M. A randomized controlled trial of four doses of transdermal estradiol for preventing postmenopausal bone loss. *Transdermal Estradiol Investigator Group*. *Obstet Gynecol* 1999;94:330-6.
265. Wells M, Sturdee DW, Barlow DH, Ulrich LG, O'Brien K, Campbell MJ, et al. Effect on endometrium of long term treatment with continuous combined oestrogen-progestogen replacement therapy: follow up study. *BMJ* 2002;325:239.
266. Wender MC, Edelweiss MI, Campos LS, Castro JA, Spritzer PM. Endometrial assessment in women using tibolone or placebo: 1-year randomized trial and 2-year observational study. *Menopause* 2004;11:423-9.
267. Wilkens J, Chwalisz K, Han C, Walker J, Cameron IT, Ingamells S, et al. Effects of the Selective Progesterone Receptor Modulator Asoprisnil on Uterine Artery Blood Flow, Ovarian Activity, and Clinical Symptoms in Patients with Uterine Leiomyomata Scheduled for Hysterectomy. *J Clin Endocrinol Metab* 2008;93:4664-71.
268. Williams ARW., Critchley HOD, Osei J, Ingamells S, Cameron IT, Han C, et al. The effects of the selective progesterone receptor modulator asoprisnil on the morphology of uterine tissues after 3 months treatment in patients with symptomatic uterine leiomyomata. *Hum Reprod* 2007;22:1694-704.
269. Winneker RC, Fensome A, Zhang P, Yudt MR, McComas CC, Unwalla RJ, et al. A new generation of progesterone receptor modulators. *Steroids* 2008;73:689-701.
270. Wollter-Svensson LO, Stadberg E, Andersson K, Mattsson LA, Odland V, Persson I. Intrauterine administration of levonorgestrel 5 and 10 microg/24 hours in perimenopausal hormone replacement therapy. A randomized clinical study during one year. *Acta Obstet Gynecol Scand* 1997;76:449-54.
271. Women's Health Initiative steering committee. Effects of conjugated equine estrogen in postmenopausal women with hysterectomy. The Women's Health Initiative randomized controlled trial. *JAMA* 2004;291:1701-12.
272. Wren BG, McFauland K, Edwards L, Edwards L, et al. Effect of sequential transdermal progesterone cream on endometrium bleeding pattern and plasma progesterone levels in postmenopausal women. *Climacteric* 2003;3:155-66.
273. Writing group for the PEPI trial. Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial. *JAMA* 1995;273:199-208.
274. Writing group for the PEPI trial. Effects of hormone replacement therapy on endometrial histology in postmenopausal women: The Postmenopausal Estrogen/progestin Interventions (PEPI) trial. *JAMA* 1996;275:370-5.
275. Writing Group for the PEPI Trial. Effects of hormone therapy on bone mineral density: results from the Postmenopausal Estrogen/Progestin Interventions (PEPI) trial. *JAMA* 1996;276:1389-96.
276. Writing group for the Women's Health Initiative investigation. Risks and benefits of estrogen plus progestin in healthy postmenopausal women. Principal results from the Women's Health Initiative randomized controlled trial. *JAMA* 2002;288:321-33.
277. Wuttke W, Seidlova-Wuttke D, Gorkow C. The Cimicifuga preparation BNO 1055 vs. conjugated estrogens in a double-blind placebo-controlled study: effects on menopause symptoms and bone markers. *Maturitas* 2003;44:S67-77.
278. Yoon BK, Kim DK, Kang Y, Kim JW, Shin MH, Na DL. Hormone replacement therapy in postmenopausal women with Alzheimer's disease: a randomized, prospective study. *Fertil Steril* 2003;79:274-80.
279. Zhou B, Sun Q, Cong R, Gu H, Tang N, Yang L, et al. Hormone replacement therapy and ovarian cancer risk: a meta-analysis. *Gynecol Oncol* 2008;108:641-51.
280. Ziel HK, Finkle WD. Increased risk of endometrial carcinoma among users of conjugated estrogens. *N Engl J Med* 1975;293:1167-70.